Table 1.

Elements of the quality target product profile (QTPP) and critical quality attribute (CQA) for the development of the atazanavir-nanostructured lipid carrier (ATZ-NLC).

QTPP
QTPP	Target	Justification
Drug delivery system	Nanostructured lipid carriers	Offers augmentation in oral bioavailability
Dosage type	Controlled release	Enhanced drug absorption will be achieved
Route of administration	Oral	Patient compliant route offering lymphatic uptake.
Drug release	More than 80%	Essential for attained optimal therapeutic activity
CQA
CQA	Target	Justification
Particle size	Less than 250 nm	Absorption and bioavailability are improved
Entrapment efficiency	More than 70%	Improved therapeutic outcome and pharmacological activity.
Drug loading	More than 8%	Improved therapeutic outcome and pharmacological activity